权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Strengthening Benefit-Cost Analyses of Substance Abuse Prevention

加强预防药物滥用的效益成本分析

基本信息

批准号：
8537748
负责人：
Daniel Max Crowley
金额：
$ 4.92万
依托单位：
DUKE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-09-01 至 2015-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8537748
关键词：
5 year old Accounting Adopted Adoption Adult Area Child Childhood Communities Cost Analysis Cost of Illness Cost-Benefit Analysis Costs and Benefits Data Economics Ethics Evaluation Foundations Funding Future Health Services Incidence Income Intervention Link Literature Logistics Longitudinal Studies Marketing Modeling National Institute of Drug Abuse Outcome Participant Policies Prevention Prevention program Preventive Intervention Price Process Program Development Public Health Randomized Research Research Personnel Research Priority Resources Review Literature Risk Risk Factors Sampling Science Services Shadowing (Histology)Social Values Substance abuse problem Support System System Time Work base boys cost design evidence base follow-up girls high risk human capital improved insight kindergarten prevent programs public health relevance reduced substance abuse social substance abuse prevention uptake

项目摘要

DESCRIPTION (provided by applicant): Substance abuse is estimated to cost the nation over $180 billion annually (French et al., 2008; Harwood, 2004; Mark et al., 2007; Schori, 2011), yet little is known about whether current evidence-based preventive interventions (EBPI) can efficiently reduce these costs (i.e., whether program benefits are greater than the cost of operating the program; Aos et al., 2004, 2011; Heckman et al., 2010). This is largely because researchers lack three components vital to conducting high-quality benefit-costs analyses (BCAs) that reliably estimate the efficiency of substance abuse (SA) prevention efforts (Bukoski et al., 1998; Crowley et al., 2011e; Karoly, 2011; O'Connell et al., 2009). These include a lack of (1) cost estimates that account for the resources needed to adopt, implement and sustain SA prevention programs, (2) estimates of the social benefits gained from reducing SA risk factors in monetary terms, and (3) guidance around best practices and research priorities for evaluating SA prevention costs and benefits. To strengthen BCA practice, the research strategy described in this proposal will estimate and model the systemic costs of a large-scale NIDA-funded SA prevention effort, estimate the societal value of targeting specific SA risk factors, and identify best practices and research priorities for BCAs of SA prevention. Further, this work will provide the foundation for a productive research program as I transition to an independent investigator.

描述（由申请人提供）：据估计，药物滥用每年使国家损失超过1800亿美元（French et al., 2008; Harwood, 2004; Mark et al., 2007; Schori, 2011），但目前对循证预防干预（EBPI）能否有效降低这些成本（即项目收益是否大于项目运营成本；Aos et al., 2004,2011; Heckman et al., 2010）知之甚少。这在很大程度上是因为研究人员缺乏进行高质量的效益-成本分析（bca）至关重要的三个组成部分，以可靠地估计药物滥用（SA）预防工作的效率（Bukoski等人，1998；Crowley等人，2011;Karoly, 2011； O'Connell等人，2009）。其中包括缺乏